长期全民食盐加碘对甲状腺疾病的疗效与安全性:来自中国大陆31个省份的流行病学证据
成人尿碘中位数177.89 μg/L,甲状腺疾病加权患病率分别为临床甲亢0.78%、亚临床甲亢0.44%、Graves病0.53%、临床甲减1.02%、亚临床甲减12.93%、甲状腺抗体阳性14.19%、甲状腺过氧化物酶抗体阳性10.19%、甲状腺球蛋白抗体阳性9.70%、甲状腺肿1.17%、甲状腺结节20.43%。碘过量仅与临床甲亢和亚临床甲减风险升高相关,碘缺乏与大多数甲状腺疾病风险升高显著相关。结论认为长期强制性USI项目在及时调整下成功预防碘缺乏病,且似乎安全。
要点
- 成人尿碘中位数为177.89 μg/L,甲状腺结节患病率20.43%,亚临床甲减12.93%。
- 碘过量仅与临床甲亢和亚临床甲减风险升高相关,碘缺乏与多数甲状腺疾病风险升高显著相关。
- 碘摄入增加与血清促甲状腺激素水平升高显著相关,与甲状腺抗体和甲状腺结节呈负相关。
核心结论
- 长期强制性USI项目在及时调整下成功预防碘缺乏病,且似乎安全。
- 在尿碘中位数稳定在最高300 μg/L的人群中,获益大于风险。
研究设计与样本
- 全国代表性横断面研究,纳入中国大陆31个省级地区78,470名18岁及以上参与者。
- 参与者接受问卷和甲状腺B超检查,并检测血清甲状腺激素、甲状腺抗体和尿碘浓度(UIC)。
主要发现
- 成人尿碘中位数为177.89 μg/L。
- 成人甲状腺疾病加权患病率:临床甲亢0.78%、亚临床甲亢0.44%、Graves病0.53%、临床甲减1.02%、亚临床甲减12.93%、甲状腺抗体阳性14.19%、甲状腺过氧化物酶抗体阳性10.19%、甲状腺球蛋白抗体阳性9.70%、甲状腺肿1.17%、甲状腺结节20.43%。
- 碘过量仅与临床甲亢和亚临床甲减风险升高相关,而碘缺乏与大多数甲状腺疾病风险升高显著相关。
- 碘摄入增加与血清促甲状腺激素水平升高显著相关,与甲状腺抗体和甲状腺结节呈负相关。
关键数值与推荐
- 尿碘中位数177.89 μg/L。
- 甲状腺疾病加权患病率:临床甲亢0.78%、亚临床甲亢0.44%、Graves病0.53%、临床甲减1.02%、亚临床甲减12.93%、甲状腺抗体阳性14.19%、甲状腺过氧化物酶抗体阳性10.19%、甲状腺球蛋白抗体阳性9.70%、甲状腺肿1.17%、甲状腺结节20.43%。
- 长期强制性USI项目在及时调整下成功预防碘缺乏病,且似乎安全;在尿碘中位数稳定在最高300 μg/L的人群中获益大于风险。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Mandatory universal salt iodization (USI) has been implemented in China for 20 years. Although iodine deficiency disorders are effectively controlled, the risk of excess iodine have been debated. Methods: A nationally representative cross-sectional study with 78,470 enrolled participants, aged 18 years or older, from all 31 provincial regions of mainland China was performed. The participants were given a questionnaire and underwent B-mode ultrasonography of the thyroid. Serum concentrations of thyroid hormones, thyroid antibodies, and urine iodine concentration (UIC) were measured. Results: The median UIC of the adult population was 177.89 μg/L. The weighted prevalence of thyroid disorders in adults were as follows: 0.78% of overt hyperthyroidism, 0.44% of subclinical hyperthyroidism, 0.53% of Graves' disease, 1.02% of overt hypothyroidism, 12.93% of subclinical hypothyroidism, 14.19% of positive thyroid antibodies, 10.19% of positive thyroid peroxidase antibodies, 9.70% of positive thyroglobulin antibodies, 1.17% of goiter, and 20.43% of thyroid nodules. Iodine excess was only associated with higher odds of overt hyperthyroidism and subclinical hypothyroidism, while iodine deficiency was significantly associated with higher odds of most thyroid disorders. In addition, increased iodine intake was significantly associated with elevated serum thyrotropin levels but was inversely associated with thyroid antibodies and thyroid nodules. Conclusions: The long-term mandatory USI program with timely adjustments is successful in preventing iodine deficiency disorders, and it appears to be safe. The benefits outweigh the risks in a population with a stable median iodine intake level of up to 300 μg/L.
引用
- Li Y, Teng D, Ba J, et al. Efficacy and Safety of Long-Term Universal Salt Iodization on Thyroid Disorders: Epidemiological Evidence from 31 Provinces of Mainland China. Thyroid. 2020. PMID: 32075540. doi:10.1089/thy.2019.0067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。